Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

News | News By Subject | News by Disease | News By Date | Search News

eNewsletter Signup

Keywords

Location

Browse Jobs

Search Job Title Only

Radius: Miles

Km80.5

Cook (Canada) Inc. To Begin First International Trial Of A Paclitaxel-Eluting Stent For Peripheral Artery Disease; New Treatment Could Benefit Millions Who Suffer From Seriously Under-Diagnosed Disease

10/19/2005 5:10:34 PM

BLOOMINGTON, Ind.--(BUSINESS WIRE)--May 3, 2005--With a U.S. trial already underway, Cook Group will expand its efforts to bring the world's first paclitaxel-eluting stent for peripheral artery disease (PAD) to market by launching an international clinical trial, company officials reported today. The global clinical investigation of Cook's Zilver(R) PTX(TM) Drug-Eluting Stent will enroll 760 patients at up to 50 investigational sites in Europe, Asia, Australia and Canada. "We see enormous potential to alleviate the pain and potential health risks associated with peripheral artery disease using Cook's unique combination of a self-expanding stent incorporating our polymer-free paclitaxel coating," noted Kem Hawkins, president of Cook Group Inc. "With the tremendous success achieved in reducing restenosis with paclitaxel-coated coronary stents, we hope to achieve comparable success in bringing this technology to millions of patients suffering from peripheral artery disease."

Read at BioSpace.com